Ozempic and other GLP-1 drugs are upending the food industry. Here’s what we can expect going forward

The use of anti-obesity medications (AOMs), led by glucagon-like peptide-1 (GLP-1) agonists like Ozempic (semaglutide), has skyrocketed over the past few years. These powerful drugs, prescribed for both type 2 diabetes and weight loss, work by mimicking a unique gut hormone that suppresses appetite and slows how fast the stomach empties after eating.

…

Many food and beverage companies are working to increase protein in their offerings—and to do so in smaller-portioned options.

Related on the SLP

How Wegovy and Ozempic could transform our food systems Viewpoint: Ideology not science — Here’s why NBC News’ factually inaccurate reporting on the ‘dangers’ of the weedkiller glyphosate sets a dangerous precedent

Kennedy faces Congressional ethics investigation for accepting massive gifts from anti-vaccine and ketamine wellness grifter

Unintended consequences: Hegseth’s proposed controversial ‘low testosterone’ screen could flag 150,000 Army men. What happens next?  

It’s the ‘juice’: What the AI data center wars are really all about

Given the studies showing that GLP-1 users tend to regain most of any lost weight within a year of stopping the drugs, food and beverage companies that are thinking about the different paths in the GLP-1 journey will be able to reach more consumers. There is great opportunity if organizations can develop new products that thread the needle, addressing the specific needs and tastes of GLP-1 users while also appealing to health-conscious consumers who are aren’t currently taking them or who have never used them.

This is an excerpt. Read the original post here